Tiziana Life Sciences Expands Phase 2 Trial for Intranasal Foralumab with UMass Dosing

Tiziana Life Sciences ( (TLSA) ) just unveiled an announcement.

On April 23, 2025, Tiziana Life Sciences announced the commencement of dosing at the University of Massachusetts, the fourth clinical site in their Phase 2 trial of intranasal foralumab for non-active secondary progressive multiple sclerosis (na-SPMS). This trial, involving prestigious institutions like Brigham and Women’s Hospital, Yale Multiple Sclerosis Center, and Johns Hopkins University, aims to evaluate the long-term safety and benefits of foralumab, with completion expected by the end of 2025. The addition of UMass reflects strong scientific and medical community interest in this novel treatment, which allows home administration and potentially improves patient compliance and outcomes.

More about Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using transformational drug delivery technologies. The company is pioneering an innovative nasal approach for immunotherapy, aiming to improve efficacy, safety, and tolerability compared to traditional intravenous delivery methods. Their lead candidate, intranasal foralumab, is the only fully human anti-CD3 monoclonal antibody currently in clinical development, with a promising safety profile and clinical response in studies.

YTD Price Performance: 70.59%

Average Trading Volume: 710,572

Technical Sentiment Signal: Strong Sell

Current Market Cap: $128.4M

Learn more about TLSA stock on TipRanks’ Stock Analysis page.